Clinically Presumed Brain Metastasis as the Initial Presentation of Prostate Cancer Harboring a BRCA2 Alteration With Subsequent Transformation to Treatment-Related Neuroendocrine Prostate Cancer: A Case Report.
Wang Yanwu Y, Wu Yingjie Y, Zhu Shaokang S, Wu Zhengrong Z et al.
Treatment-related neuroendocrine prostate cancer (t-NEPC) is an aggressive, therapy-resistant phenotype for which no standard treatment has been established. Intracranial metastasis from prostate cancer is uncommon, particularly as the initial presentation. In March 2020, a 62-year-old man presented to Nanfang Hospital, Southern Medical University, Guangzhou, China, with dizziness and blurred vision. Imaging showed disseminated prostate cancer and an intracranial lesion that was clinically presumed to represent metastasis but was not biopsied. Prostate biopsy demonstrated acinar adenocarcinoma (Gleason score 5 + 4 = 9; Grade Group 5). After androgen deprivation therapy, docetaxel, and subsequent abiraterone, a February 2022 transurethral resection specimen showed large-cell neuroendocrine carcinoma, establishing t-NEPC in the prostate. Immediately before TURP, total PSA was 0.369 ng/mL and NSE was 30.3 ng/mL. Tumor-only next-generation sequencing of the resection specimen detected BRCA2 p.I605fs and TP53 p.A83fs alterations with RB1 and PTEN copy-number losses; germline status was not assessed. Etoposide/cisplatin was initiated in March 2022, and continuous olaparib began on April 14, 2022 during cycle 2. Clinical improvement and approximately 11 months of disease stability were observed, but the contribution of either treatment cannot be isolated. The disease subsequently progressed, and the patient died 39 months after the initial diagnosis. This case underscores the distinction between a clinically presumed intracranial metastasis and histologically confirmed t-NEPC. It also highlights the diagnostic value of re-biopsy at progression and the need for cautious interpretation of biomarker changes and overlapping treatments. Prospective clinicopathological and molecular data are needed to refine the diagnosis and management of t-NEPC.